全身炎症反应指标作为异基因造血细胞移植前预后风险因素的重要性
该前瞻性分析纳入2201例连续接受首次异基因造血细胞移植(alloHCT)的患者,于入院时记录C反应蛋白(CRP)、血清白蛋白(sALB)、改良格拉斯哥预后评分(mGPS)和体重指数(BMI),并统计分析其与总生存/无进展生存(OS/PFS)、非复发死亡(NRM)、复发及移植物抗宿主病(GvHD)的关系。多变量模型显示mGPS 1和mGPS 2是OS和PFS的显著风险因素,仅mGPS 2影响NRM。移植前全身炎症反应标志物及其组合(mGPS)与临床结局呈高度显著关联,可能丰富现有alloHCT风险评分。
要点
- mGPS 1(SHR 1.301)和mGPS 2(SHR 1.915)是OS的显著风险因素(p < 0.001)。
- mGPS 1(SHR 1.202)和mGPS 2(SHR 1.765)是PFS的显著风险因素。
- 仅mGPS 2(HR 1.671;p < 0.001)显示对NRM的影响。
核心结论
- 移植前全身炎症反应标志物及其组合(mGPS)与临床结局呈高度显著关联,可能丰富现有alloHCT风险评分。
研究设计与样本
- 前瞻性分析纳入2201例连续接受首次异基因造血细胞移植(alloHCT)的患者,于入院时记录CRP、sALB、mGPS和BMI,并与EBMT评分及HCT特异性合并症指数(HCT-CI)一同统计分析。
主要发现
- CRP升高者占34.8%,sALB低者占17%,BMI升高(≥35 kg/m2)者占2.9%,BMI极低(<18.5 kg/m2)者占3%。
- mGPS评分1者占24%,评分2者占11%。
- 多变量模型显示mGPS 1(SHR 1.301)和mGPS 2(SHR 1.915)是OS的显著风险因素(p < 0.001)。
- mGPS 1(SHR 1.202)和mGPS 2(SHR 1.765)是PFS的显著风险因素。
- 仅mGPS 2(HR 1.671;p < 0.001)显示对NRM的影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic inflammatory response (SIR) measures are known prognostic values in patients with solid tumours. Little is known about their impact in haematological diseases or allogeneic haematopoietic cell transplantation (alloHCT). Therefore, we evaluate the association of pretransplant inflammatory markers with the clinical outcome in a prospective analysis of alloHCT. We included 2201 consecutive patients undergoing their first alloHCT. At admission, C-reactive protein (CRP), serum albumin (sALB), a composite inflammatory score (modified Glasgow prognostic score, mGPS) and the body mass index (BMI) were recorded. These, the EBMT score and the HCT-specific comorbidity index (HCT-CI) were statistically analysed for overall/progression-free survival (OS/PFS), non-relapse mortality (NRM), relapse and graft-versus-host disease (GvHD). CRP was increased in 34.8%, 17% had a low sALB, 2.9% an increased (≥35 kg/m2) and 3% a very low BMI (<18.5 kg/m2). For mGPS, we observed score 1 (24%) and 2 (11%). A multivariable model explored mGPS 1 (SHR 1.301) and mGPS 2 (SHR 1.915) as significant risk factors (p < 0.001) for OS and for PFS (mGPS 1 (SHR 1.202); mGPS 2 (SHR 1.765)). Only mGPS 2 (HR 1.671; p < 0.001) revealed influence on NRM. Pretransplant SIR markers and their combination (mGPS) displayed a highly significant association with clinical outcome, possibly enriching present alloHCT risk scores.
引用
- Bertz H, Sahlmann J, McMillan DC, et al. The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation. Br J Haematol. 2025. PMID: 40731308. doi:10.1111/bjh.70049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。